Apyx Medical Corp — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Apyx Medical reported Q2 2026 total revenue of $13.9M (up 22% YoY), with Surgical Aesthetics segment growing 28% to $12.4M, driven by AYON platform sales and international generator revenue. The company received expanded FDA 510(k) clearance for AYON power liposuction capability and commenced limited commercial launch with initial June 2026 shipments to key surgeons. Net loss improved to $3.2M (vs. $3.8M prior year); Adjusted EBITDA loss was $0.7M (vs. $2.0M prior year). Cash position: $27.6M as of June 30, 2026. Full-year 2026 guidance reaffirmed: $59.0M–$60.0M total revenue (vs. $52.8M in 2025); Surgical Aesthetics $54.0M–$55.0M; operating expenses <$45.0M.
Why this rating
22% revenue growth and FDA clearance for new capability are meaningful positives; however, company still unprofitable with $3.2M loss. Revenue of $13.9M annualized ~$55M is ~69% of market cap ($79.8M), typical for small medtech. AYON launch phase, loss improvement, and cash burn ($3.5M ops cash Q2) provide moderate near-term trajectory upside, but not transformational yet.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.